BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Credit available for this activity expires: 3/21/24
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989323?ecd=bdc_podcast_libsyn_mscpedu
Create your
podcast in
minutes
It is Free